← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
HomeStocksKTTARevenue History
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

KTTA logoPasithea Therapeutics Corp. (KTTA) Revenue History

Annual and quarterly revenue from 2020 to 2024

TTM Revenue
$0
0
YoY Growth
-
Latest Quarter
$0
Q3 2025
QoQ Growth
-

Compound Annual Growth Rate (CAGR)

3-Year-
5-Year-
10-Year-
Highest Annual Revenue$15K (2021)
Highest Quarter$15K (Q4 2021)

Loading revenue history...

KTTA Revenue Growth

1-Year Growth
-
3-Year CAGR
-
5-Year CAGR
-
10-Year CAGR
-
TTM vs Prior Year-
Peak Annual Revenue$15,062 (2021)

Download Historical Data

5 records • Includes OHLCV + Technical Indicators (MA50, MA200, RSI)

Free sign in required to download data

KTTA Revenue Analysis (2020–2024)

As of May 8, 2026, Pasithea Therapeutics Corp. (KTTA) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.

Looking at the longer-term picture, KTTA's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $15,062 in 2021.

When compared to Healthcare sector peers including ATAI (+811.8% YoY), and NRXP. Compare KTTA vs ATAI →

KTTA Revenue vs Peers

Revenue metrics vs comparable public companies

CompanyTTM RevenueYoY Growth5Y CAGROp. MarginCompare
KTTA logoKTTACurrent$0---
ATAI logoATAI$308,000+811.8%--33341.2%
NRXP logoNRXP$1M---1324.4%
Best in groupLowest in group

KTTA Historical Revenue Data (2020–2024)

Showing 5 of 5 records
Year Revenue YoY % Gross Profit Gross Margin Op. Income Op. Margin
2024$0-$0-$-14,249,962-
2023$0-$0-$-15,979,361-
2022$0-100.0%$-5,094-$-12,588,971-
2021$15K-$-2,213-14.7%$-4,507,413-29925.7%
2020$0-$0-$-61,476-

See KTTA's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is KTTA Undervalued?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

Compare KTTA vs DBVT

Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..

Start Comparison

KTTA — Frequently Asked Questions

Quick answers to the most common questions about buying KTTA stock.

Is KTTA's revenue growth accelerating or slowing?

KTTA TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.

What is KTTA's long-term revenue growth rate?

Pasithea Therapeutics Corp.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.

How is KTTA's revenue distributed by segment?

KTTA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2020-2024 are available for download. Segment mix reveals concentration and diversification trends.

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.

KTTA Revenue Over Time (2020–2024)